Participants receiving a three-day course of remdesivir (Veklury, Gilead Sciences) had an 87% reduction in risk of COVID-19-related hospitalization or all-cause death by Day 28 and an 81% reduction in the risk of COVID-19-related medical visits or all-cause death by Day 28 compared to placebo.